Hemophilia A Treatment market size was estimated at USD 8 billion in 2016

Digg This
Reddit This
Stumble Now!
Buzz This
Vote on DZone
Share on Facebook
Bookmark this on Delicious
Kick It on DotNetKicks.com
Shout it
Share on LinkedIn
Bookmark this on Technorati
Post on Twitter
Google Buzz (aka. Google Reader)
Contact Us
Polaris Market Research
Polaris Market Research 30 Wall Street 8th Floor N
New York City
United States 10005 
United States
Phone:+1-646-568-9980
ketki@polarismarketresearch.com

Hemophilia A patients have begun to shift from short acting to EHL factors and from on demand therapies to prophylactics.

According to the US Centers for Disease Control and Prevention, hemophilia A occurs in 1 in 5,000 live male births. Hemophilia A is about four times as common as hemophilia B. The number of people with hemophilia in the United States is estimated to be about 20,000 individuals. Approximately 75% of people with hemophilia around the world still receive inadequate treatment or have no access to treatment.

As of January 2018, there are over 450 reported Clinical Trials for Hemophilia A with 50+ trials currently actively ongoing. Out of all the trials, 120+ studies are funded by the pharmaceutical companies alone. The major players with drugs in Phase III are Alnylam Pharmaceuticals, Sanofi (Genzyme), BioMarin Pharmaceutical, Hoffmann-La Roche, Sinocelltech Ltd., Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd, Octapharma, LFB USA, Inc., Novo Nordisk A/S, Pfizer and others.

Polaris Market Research expects that with the expected launch of the promising treatments, the market is expected to expand in Hemophilia A segment. The United States dominates the Hemophilia A treatment market followed by Europe 5 and Japan. The prophylaxis segments are predicted to be the fastest growing segment whereas the on-demand therapy segment is expected to contribute close to ~50% to the market during the forecast period. With the increase in the R&D investments and rising drug innovations in this field, the market is expected to significantly expand in the next five years.

RNA based therapeutics and curative gene therapies are rapidly progressing through clinical development and are seen as an attractive segment of this market.

Polaris Market Research has provided the forecasts of the Global Hemophilia A Market from 2016-2022. The major segments which has been investigated in the global market from 2016-2022 are:

Market Analysis by Hemophilia A treatment
Market Analysis by Treatments/Marketed Drugs
Market Analysis by G7 countries

The Marketed Therapies undertaken in forecast from 2016-2022 are:
Afstyla Sales Forecast-2016-2022
Eloctate Sales Forecast-2016-2022
Hemlibra Sales Forecast-2016-2022
Kogenate FS Sales Forecast-2016-2022
Kovaltry Sales Forecast-2016-2022
Nuwiq Sales Forecast-2016-2022
Obizur Sales Forecast-2016-2022

The Major Indications in Hemophilia A Therapy area:
Prophylaxis-Market Forecast 2016-2022
On-demand therapy-Market Forecast 2016-2022
Inhibitor therapy- Market Forecast 2016-2022

Comments are closed.